Results 21 to 30 of about 1,334 (146)

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials

Ophthalmology Science
Purpose: To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME).
Usha Chakravarthy, FRCOphth, PhD, Varun Chaudhary, MD, FRCS(C), Srinivas R. Sadda, MD, Colin S. Tan, FRCOphth, FRCSEd (Ophth), Stela Vujosevic, MD, PhD, Sascha Fauser, MD, Kara Gibson, PhD, Carl Glittenberg, MD, Nancy Holekamp, MD, FASRS, Ben Lanza, PhD, Andreas Maunz, PhD, Jeffrey R. Willis, MD, PhD, Rishi P. Singh, MD   +12 more
doaj   +1 more source

Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan

Scientific Reports, 2023
This multicenter study aimed to assess the short-term effectiveness and safety of faricimab in treatment-naïve patients with wet age-related macular degeneration (wAMD) in Japan.
Ryo Mukai, Keiko Kataoka, Koji Tanaka, Yasunori Miyara, Ichiro Maruko, Makiko Nakayama, Yuto Watanabe, Akiko Yamamoto, Yu Wakatsuki, Hajime Onoe, Sorako Wakugawa, Nobuhiro Terao, Taiji Hasegawa, Nozomu Hashiya, Moeko Kawai, Ruka Maruko, Kanako Itagaki, Jyunichiro Honjo, Annabelle A. Okada, Ryusaburo Mori, Hideki Koizumi, Tomohiro Iida, Tetsuju Sekiryu   +22 more
doaj   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors

British Journal of Pharmacology, Volume 182, Issue S1, Page S259-S306, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Chloe J. Peach, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Annie Beuve, Peter Brouckaert, Clare Bryant, John C. Burnett, Richard W. Farndale, Andreas Friebe, John Garthwaite, Adrian J. Hobbs, Gavin E. Jarvis, Laura Kilpatrick, Doris Koesling, Michaela Kuhn, Birgit Leitinger, David MacEwan, Tom P. Monie, Lincoln R. Potter, Michael Russwurm, Harald H. H. W. Schmidt, Johannes‐Peter Stasch, Scott A. Waldman   +31 more
wiley   +1 more source

YOSEMITE and RHINE

Ophthalmology Science, 2022
Purpose: Faricimab is a novel anti–angiopoietin-2 and anti–vascular endothelial growth factor (VEGF) bispecific antibody with high affinities and specificities for both VEGF and angiopoietin-2.
Nicole Eter, MD, PhD, Rishi P. Singh, MD, Francis Abreu, PhD, Kemal Asik, PhD, Karen Basu, PhD, Caroline Baumal, MD, Andrew Chang, PhD, Karl G. Csaky, MD, Zdenka Haskova, MD, PhD, Hugh Lin, MD, Carlos Quezada Ruiz, MD, Paisan Ruamviboonsuk, MD, David Silverman, MSc, MRCOphth, Charles C. Wykoff, MD, PhD, Jeffrey R. Willis, MD, PhD   +14 more
doaj   +1 more source

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, Volume 53, Issue 9, Page 1156-1167, December 2025.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies   +9 more
wiley   +1 more source

Faricimab in Neovascular AMD

, 2023
Abstract Purpose Assess short-term real-world outcomes in neovascular aged-related macular degeneration (nAMD) treated with novel faricimab. Methods Retrospective case series of nine patients with nAMD (11 eyes) treated with faricimab between May and November 2022.
Paulo Eduardo Stanga, Francisco Javier Valentin Bravo, Sebastian Stanga, Ursula Reinstein, Salvador Pastor Idoate, Susan Downes   +5 more
openaire   +1 more source

Stimuli‐responsive systems: A focus on controlled drug delivery for posterior segment ocular disease

Responsive Materials, Volume 3, Issue 4, November 2025.
This review highlights recent advances in stimuli‐responsive drug delivery for posterior segment diseases, focusing on mechanisms and potential. It also explores mechanically interlocked molecules and bioorthogonal reactions as novel approaches. Challenges and future perspectives are discussed, aiming to bridge the gap between research and clinical ...
Chengzhi Zhang, Jiayi Hou, Yameng Zhao, Yiwen Wang, Kexin Wang, Siyu Li, Yange Wang, Jiehao Zhang, Shenao Ding, Chenxu Zhang, Zongming Song, Ye Tao   +11 more
wiley   +1 more source

Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis

Acta Ophthalmologica, Volume 103, Issue 7, Page 741-763, November 2025.
Abstract The aim of this review was to evaluate the comparative efficacy of intravitreal anti‐vascular endothelial growth factor (anti‐VEGF) therapy for neovascular AMD. We searched 12 literature databases for randomised clinical trials (RCT) on anti‐VEGF therapy for neovascular AMD and extracted data on: change from baseline to 12 months in best ...
Emilie T. S. Butler, Andreas Arnold‐Vangsted, Marianne G. Schou, Rodrigo Anguita, Jakob Bjerager, Enrico Borrelli, Lasse J. Cehofski, Lorenzo Ferro Desideri, Elon H. C. van Dijk, Carsten Faber, Jakob Grauslund, Javad N. Hajari, Josef Huemer, Oliver N. Klefter, Marie Krogh Nielsen, M. Cem Sabaner, Miklos Schneider, Yousif Subhi   +17 more
wiley   +1 more source

Analysis of the aqueous humor before and after the administration of faricimab in patients with nAMD

Scientific Reports
This study aimed to evaluate the changes in cytokine levels in the aqueous humor and factors of treatment resistance following intravitreal faricimab injection in treatment-naïve patients with neovascular age-related macular degeneration.
Ryo Nonogaki, Hikaru Ota, Jun Takeuchi, Yuyako Nakano, Ai Fujita Sajiki, Takahito Todoroki, Koichi Nakamura, Hiroki Kaneko, Koji M. Nishiguchi   +8 more
doaj   +1 more source

Uveitis Following Intravitreal Injections of Faricimab: A Case Report

Ocular Immunology and Inflammation, 2023
Faricimab, a novel pharmaceutical agent targeting both angiopoietin-2 and vascular endothelial growth factor-A pathways, has gained approval for treating neovascular age-related macular degeneration and diabetic macular oedema. While clinical trials have demonstrated its favorable safety profile, this research presents two cases of hypertensive uveitis
Filomena, Palmieri, Saad, Younis, Aseel, Bedan Hamoud, Lorenzo, Fabozzi   +3 more
openaire   +2 more sources